Community protocol · LL-37
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: LL37 · Human cathelicidin
Sources checked: 27 August 2026
This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Quick context
Part of innate immunity; antimicrobial, inflammatory and wound-repair signalling are under study.
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Amounts, timing and cycles
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Different amounts circulate online; no regulator-confirmed safe or effective dose exists.
Profile evidence level: preclinical.
Community claims about time of day, fasting windows or training intervals are not validated clinical standards.
No individual recommendation.
Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community sourceReconstitution and U-100 conversion
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
LL-37 is classified as “Endogenous antimicrobial host-defence peptide”. Part of innate immunity; antimicrobial, inflammatory and wound-repair signalling are under study. This describes the investigated pathway but does not validate a community use, amount, route or combination.
Researchers study how a naturally occurring defence peptide attacks bacteria and affects inflammation signals, similar to a first line of defence for skin and mucous membranes. Bacterial growth and immune markers are measured in the lab.
This studies how a peptide adjusts immune cell activity, similar to a dial that strengthens or dampens the immune response. Immune cell counts and inflammation markers are measured in studies.
This studies how a peptide influences the migration of cells toward an injury site, similar to workers rushing to a construction site. Speed and extent of cell migration are measured in lab models.
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
People report subjectively perceived digestive improvements after using gastric-protective or immune-modulating peptides, usually without objective diagnostics. Such self-observations do not establish a confirmed effect on the gut.
People report perceived faster healing of injuries or tendon problems after using certain peptides, usually without a control group or objective measurement. Such individual reports do not establish actual efficacy or safety.
Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.
Adverse effects and risk boundaries
Exclusion groups and professional assessment
Monitoring and laboratory markers
Evidence boundary
Antimicrobial and inflammatory effects remain under study, without a confirmed clinical use.
Published evidence
Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.
LL-37 belongs to innate immune defence, distinguishing it from adaptively acting immune peptides such as thymosin alpha-1.
Storage and stability
Troubleshooting and error sources
Regulatory status and WADA
No FDA- or EMA-approved medicinal product; efficacy and safety are not established.
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
Frequently asked questions
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
